Polymorphisms in the P450 c17 (17-hydroxylase/17,20-Lyase) and P450 c19 (aromatase) genes: association with serum sex steroid concentrations and bone mineral density in postmenopausal women.

The CYP 17 and CYP 19 genes encode 17alpha-hydroxylase/17,20-lyase and aromatase, respectively, both involved in sex hormone synthesis. We investigated the association between 2 common polymorphisms in 1) the promoter region (T-->C substitution) of CYP 17, and 2) exon 3 (G-->A) of CYP 19, bone mineral density (BMD) and serum androgen/estradiol, in a case-control study of 252 postmenopausal women aged 64.5 +/- 9.2 yr (mean +/- SD). There was no significant difference in serum estradiol concentrations between cases (n = 136) and controls (n = 116). The CYP 19 genotype was significantly associated with serum estradiol (P = 0.002). Women with the AA genotype had higher serum estradiol concentrations compared with those with the GG genotype (P = 0.03). In older women, those with the CYP 19 GA and GG genotypes had an increased prevalence of osteoporosis (P = 0.04) and fractures (P = 0.003). We found no significant association between CYP 17 genotype and serum androgens and estradiol concentrations. However, a significant association was seen between BMD values at the femoral neck with CYP 17 genotype in cases (P = 0.04) and in the whole study population (P = 0.012). Subjects with the CC genotype had significantly lower BMD (mean +/- SD: TT, 0.7 +/- 0.16; CC, 0.6 +/- 0.08 g/cm(2); P = 0.006). In conclusion, both CYP 17 and CYP 19 are candidate genes for osteoporosis in postmenopausal women.

[1]  S. Ortolani,et al.  Genetics of osteoporosis , 1994, Calcified Tissue International.

[2]  S. Ralston,et al.  Genetic determinants of susceptibility to osteoporosis. , 2003, Endocrinology and metabolism clinics of North America.

[3]  R. Doll,et al.  Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial , 2003, BMJ : British Medical Journal.

[4]  S. Mohan,et al.  Quantitative Trait Loci for Bone Density in Mice: The Genes Determining Total Skeletal Density and Femur Density Show Little Overlap in F2 Mice , 2002, Calcified Tissue International.

[5]  E. Imyanitov,et al.  CYP17 genetic polymorphism in endometrial cancer: are only steroids involved? , 2002, Cancer letters.

[6]  Sundeep Khosla,et al.  Sex steroids and the construction and conservation of the adult skeleton. , 2002, Endocrine reviews.

[7]  J. Parry,et al.  The CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis. , 2002, Mutagenesis.

[8]  O. Cussenot,et al.  Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways , 2001, Cancer.

[9]  P. Kantoff,et al.  The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[10]  L. Kuller,et al.  A Common Promoter Variant in the Cytochrome P450c17α (CYP17) Gene Is Associated with Bioavailable Testosterone Levels and Bone Size in Men , 2001 .

[11]  M. Brandi,et al.  Polymorphism of the aromatase gene in postmenopausal Italian women: distribution and correlation with bone mass and fracture risk. , 2001, The Journal of clinical endocrinology and metabolism.

[12]  D. Eccles,et al.  Polymorphic variation in CYP19 and the risk of breast cancer. , 2001, Carcinogenesis.

[13]  E. Simpson,et al.  Role of aromatase in sex steroid action. , 2000, Journal of molecular endocrinology.

[14]  W. Willett,et al.  A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk , 2000, International journal of cancer.

[15]  P. Lønning,et al.  Genetic variants of CYP19 (aromatase) and breast cancer risk , 2000, Oncogene.

[16]  R. Weinstein,et al.  New Developments in the Pathogenesis and Treatment of Steroid‐Induced Osteoporosis , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[17]  W. Miller,et al.  Molecular modeling of human P450c17 (17alpha-hydroxylase/17,20-lyase): insights into reaction mechanisms and effects of mutations. , 1999, Molecular endocrinology.

[18]  P. Lønning,et al.  CYP17 and breast cancer risk: the polymorphism in the 5' flanking area of the gene does not influence binding to Sp-1. , 1999, Cancer research.

[19]  K. Buetow,et al.  Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk , 1999, British Journal of Cancer.

[20]  J. Goméz,et al.  Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. , 1997, The Journal of clinical endocrinology and metabolism.

[21]  E. Simpson,et al.  Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. , 1995, The Journal of clinical endocrinology and metabolism.

[22]  W. Miller,et al.  Analysis of the aromatase cytochrome P450 gene in human breast cancers. , 1994, Journal of molecular endocrinology.

[23]  J. Little,et al.  Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. , 1994, Human molecular genetics.

[24]  S. Cummings,et al.  Bone density at various sites for prediction of hip fractures , 1993, The Lancet.

[25]  M. Waterman,et al.  17α-Hydroxylase/17,20-Lyase Deficiency: From Clinical Investigation to Molecular Definition* , 1991 .

[26]  J. Mathis,et al.  Structural analysis of the gene encoding human aromatase cytochrome P-450, the enzyme responsible for estrogen biosynthesis. , 1989, The Journal of biological chemistry.

[27]  J. Hopper,et al.  Genetic determinants of bone mass in adults. A twin study. , 1987, The Journal of clinical investigation.

[28]  O. Hill.  A Twin Study , 1968, British Journal of Psychiatry.